Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 27-42 , February 2007

Early rheumatoid arthritis: strategies for prevention and management

  • Bernard Combe, MD, PhD (Professor of Rheumatology)

      Affiliations

    • Corresponding Author InformationTel.: +33 4 67 33 87 10; Fax: +33 4 67 33 73 11.

References 

  1. Visser H. Early diagnosis of rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2005;19:55–72
  2. Dixon NG, Symmons DPM. Does early rheumatoid arthritis exist?. Best Practice and Research Clinical Rheumatology. 2005;19:37–53
  3. Huizinga TW, Machold KP, Breedveld FC, et al. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis and Rheumatism. 2002;46:1155–1159
  4. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Annals of the Rheumatic Diseases. 2006 Jan 5;[Epub ahead of print]
  5. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2005;19:137–146
  6. Combe B. Should patients with recent-onset polyarthritis receive aggressive treatment?. Joint, Bone, Spine: Revue du Rhumatisme. 2004;71:475–480
  7. Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism. 2000;43:495–505
  8. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis and Rheumatism. 2002;46:347–356
  9. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying anti-rheumatic drugs: five-year experience from the FIN-RACo study. Arthritis and Rheumatism. 2004;50:2072–2081
  10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and Rheumatism. 2005;52:3381–3390
  11. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine. 2000;343:1594–1602
  12. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681
  13. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism. 2004;50:1400–1411
  14. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. The American Journal of Medicine. 2001;111:446–451
  15. Bukhari MA, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis and Rheumatism. 2003;48:46–53
  16. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–914
  17. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–269
  18. Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the Rheumatic Diseases. 2002;61:290–297
  19. European Action Towards Better Musculoskeletal Health: A Public Health Strategy to Reduce the Burden of Musculoskeletal Conditions. A Bone and Joint Decade Report, 2004. The European Bone and Joint Health Strategies Project. The Bone and Joint Decade, Lund, Sweden. Available at: http://ec.europa.eu/health/ph_project/2000/promotion/fp_promotion_2000_frep_15_en.pdf.
  20. Guillemin F, Suurmeijer T, Krol B, et al. Functional disability in early rheumatoid arthritis: description and risk factors. Journal of Rheumatology. 1994;21:1051–1055
  21. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. The Journal of Rheumatology. 1991;18:1298–1306
  22. Jantti J, Aho K, Kaarela K, et al. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis in the first years of the disease. Rheumatology. 1999;38:423–430
  23. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis and Rheumatism. 2000;43:22–29
  24. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36:1082–1088
  25. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58:220–225
  26. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. The New England Journal of Medicine. 1995;333:137–141
  27. Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Annals of the Rheumatic Diseases. 2003;62:291–296
  28. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism. 2002;46:1443–1450
  29. St Clair EW, van der Heijde DM, Smolen JS, et al. Active-controlled study of patients receiving infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism. 2004;50:3432–3443
  30. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism. 2006;54:26–37
  31. Welsing PM, Landewe RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism. 2004;50:2082–2093
  32. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: one year TEMPO results. Annals of the Rheumatic Diseases. 2005;64:1582–1857
  33. Pinals RS, Masia T, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis and Rheumatism. 1981;24:1308–1315
  34. Prevoo ML, van Gestel AM, van T Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 1996;35:1101–1105
  35. Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Annals of the Rheumatic Diseases. 2000;59:521–528
  36. McQueen FM, Benton N, Perry D, et al. Bone oedema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2003;48:1814–1827
  37. Ejbjerg B, Narvestad E, Rostrup E, et al. Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:1097–1106
  38. Klareskog L, Stolt P, Lundberg K, et al. New model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and Rheumatism. 2006;54:38–46
  39. Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Systematic Reviews. 2004;CD003789
  40. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Systematic Reviews. 2004;CD000189
  41. Quinn MA, Green MJ, Marzo-Ortega H, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis and Rheumatism. 2003;48:3039–3045
  42. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Annals of Internal Medicine. 2002;136:1–12
  43. Rau R, Wassenberg S, Zeidler H LDPT-Study Group. Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis – preliminary results of a multicenter, randomized, parallel, double blind study. Zeitschrift für Rheumatologie. 2000;59(supplement 2):II/90–II/96
  44. Proudman SM, Conaghan PG, Richardson C, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intra-articular corticosteroids compared with sulfasalazine alone. Arthritis and Rheumatism. 2000;43:1809–1819
  45. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2000;39:975–981
  46. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis and Rheumatism. 1994;37:1492–1498
  47. Ottawa Panel . Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercises in the management of rheumatoid arthritis in adults. Physical Therapy. 2004;84:934–972
  48. Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Systematic Reviews. 2000;CD000322
  49. Steultjens EM, Dekker J, Bouter LM, et al. Occupational therapy for rheumatoid arthritis. Cochrane Database Systematic Reviews. 2004;CD003114
  50. Hafstrom I, Ringertz B, Spangberg A, et al. A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology (Oxford). 2001;40:1175–1179
  51. Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Systematic Reviews. 2003;CD003688
  52. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism. 2002;46:357–365
  53. Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis and Rheumatism. 2001;44:1736–1743
  54. Dixey J, Solymossy C, Young A. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). The Journal of Rheumatology Supplement. 2004;69:48–54
  55. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Annals of the Rheumatic Diseases. 2003;62:120–126
  56. Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Medical Care. 1998;36:513–522
  57. Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. Journal of Rheumatology. 1997;24:2283–2290

PII: S1521-6942(06)00115-X

doi: 10.1016/j.berh.2006.08.011

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 27-42 , February 2007

Article Tools